Supply agreement with Regeneron for GRWD5769 clinical trial

Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab) Combination of First-in-Class ERAP1 Inhibitor and Anti-PD-1 Monoclonal Antibody to be Studied...
Read More

Brett Carter joins board of Directors of Australian subsidiary

Grey Wolf Therapeutics, a biotechnology company generating entirely novel immune responses through targeted neoantigen creation, today announced the appointment of Brett Carter as a Non-Executive Director to the board of...
Read More

Dr Cassian Yee join Clinical Advisory Board

Grey Wolf Therapeutics Announces Appointment of Cassian Yee to Clinical Advisory Board Pioneer in the Field of Immuno-Oncology Brings Unique Expertise to Support Company’s Advancement of Lead ERAP1 Inhibitor Development...
Read More

Formation of our Clinical Advisory Board

Grey Wolf Therapeutics Announces Formation of Clinical Advisory Board in Anticipation of Advancing First-in-Class Immuno-Oncology Approach into the Clinic Distinguished Thought Leaders in Field of Oncology to Support Planned Initiation...
Read More

Preclinical data on first-in-class ERAP1 inhibitors presented at SITC

Grey Wolf Therapeutics today announced the presentation of promising preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 at the 36th Annual Meeting of the Society for Immunotherapy...
Read More

GWT to present preclinical data at SITC 2021

Presented findings will highlight the ability of the company’s novel ERAP1 inhibitors to significantly increase the diversity of T cell receptors in the tumor, drive synergistic upregulation of translationally relevant...
Read More